Israel's Cannabis Export Industry (2026)

For years the honest summary of Israel's cannabis export industry was that it had produced more press releases than tonnage. That summary is now out of date — but not in the way the original bull case predicted. Israel's largest operators are earning real money in Europe, and specifically in Germany. Whether that counts as exporting is the question this guide exists to answer.

This guide is informational and is not investment or legal advice. Company figures are drawn from public filings and releases; readers should consult the originals before relying on them.

The original thesis, and why it stalled

Israel built a pharmaceutical-style regulatory regime — IMC-GAP, IMC-GMP and the standards around them — partly to position domestic producers for export into regulated European markets. The reasoning was straightforward: Israeli quality standards plus decades of research credibility should convert into European market share, above all in Germany.

For most of the decade that followed, it did not. Industry analysis found that only a small handful of exporters — chiefly Panaxia and BOL Pharma — had moved limited volumes into markets such as Australia, Germany and France (Cannamonitor). The first commercial medical cannabis shipment from Israel to Germany was treated as a landmark event in its own right (Jerusalem Post) — which tells you how thin the flow was.

Three forces blunted the thesis at once. Booming domestic demand absorbed local supply. Global oversupply, particularly from Canada, made higher-cost Israeli flower uncompetitive abroad. And the financial strain showed at home: Univo, one of the companies that had secured export approval, filed an insolvency petition citing debts of roughly NIS 50 million (Cannamonitor).

What changed in 2025–26: Germany

The 2025 results of Israel's two most internationally visible operators tell a different story from the one above.

IM Cannabis reported total 2025 revenue of about C$54.7 million, of which German revenue was roughly C$36.3 million — up more than 134% year on year and over 66% of group revenue — alongside the company's first positive operating cash flow, at C$4.7 million (IM Cannabis investor relations). A company founded on the Israeli market now derives two-thirds of its sales from Germany.

InterCure, the larger of the two, reported over NIS 270 million in 2025 revenue with NIS 47 million in adjusted EBITDA and positive operating cash flow, and recorded its first meaningful German revenue during the year, which it expects to continue into 2026 behind premium branded launches there (InterCure / GlobeNewswire). The same filings describe an agreement to acquire Botanico, expected to add more than NIS 30 million of revenue in the second half of 2026.

So the export story is no longer a rounding error. It is, however, a different kind of story than the one told in 2020.

The distinction that matters: German revenue is not Israeli tonnage

This is the point most coverage skips. What grew in 2025 was revenue booked through German subsidiaries and distribution platforms, not necessarily flower grown in Israel and shipped to Europe. IM Cannabis operates a multi-country platform spanning Israel and Germany; InterCure's German revenue comes from branded product launched into that market. Public disclosures generally do not break out how much of the underlying product originates in Israeli cultivation versus third-country supply routed through a German entity.

That distinction changes the conclusion entirely. Israel's leading cannabis companies have successfully internationalised. Israel's cannabis cultivation base has not obviously become an export engine. Those are two different achievements, and only the first has clearly happened.

Who actually holds the export credentials

Selling medical cannabis into the EU requires EU-GMP certification, and the Israeli list is short. BOL Pharma obtained the standard first; Panaxia followed in June 2020, becoming the first publicly held Israeli cannabis company to hold it (PR Newswire). Panaxia went on to become the first Israeli company granted a marketing permit for medical cannabis products in Germany (PR Newswire), and signed a five-year agreement with Germany's AxioNovo GmbH under which Panaxia manufactures to EU-GMP standard for the German market (Business of Cannabis).

Panaxia's more recent trajectory is telling in a different way: the company announced it would exit low-profit activities in Israel to concentrate on manufacturing and exporting to Europe (Business of Cannabis). Export is not just an upside for Israeli producers any more — for some of them it is the escape route from a squeezed domestic market.

Meanwhile, Israel is still a net importer

None of this displaces the structural fact. Across the three years from July 2023 to June 2026, Canada alone exported cannabis to Israel worth CAD$107.95 million, against CAD$37.05 million from every other country combined, according to figures recorded in Israel's own anti-dumping decision (StratCann, August 2026). A country importing at that scale to supply its own patients is not a net exporter, whatever its companies earn abroad. That dependence is also why trade policy is cannabis policy in Israel — the anti-dumping fight over Canadian imports has run through two rounds since 2024 and is live again. The full picture is in our guide to Israel's cannabis imports and supply and in the Regulation hub.

What would have to change

For Israel to become an exporter in the literal sense — domestically grown flower shipped out in volume — three things would have to move together: domestic production costs would have to fall far enough to compete with Canadian and Portuguese supply; more Israeli facilities would need EU-GMP certification rather than the current handful; and the domestic market would have to stop absorbing local output, which the record patient base makes unlikely in the near term. None of the three is impossible. None is close.

The takeaway

Israel's comparative advantage in cannabis remains research, standards and corporate execution — not low-cost production. What 2025–26 proved is that Israeli companies can build profitable businesses in Europe. What it did not prove is that Israel can export its way out of an import-dependent domestic market. Read the German numbers as evidence of good corporate strategy, not of an export industry.

For the businesses behind these figures, see our profiles of InterCure / Canndoc and IM Cannabis, the full company directory, and the Companies hub; for the equity angle, see investing in Israeli cannabis stocks.